药物性肝损伤发病机制研究进展

王海珍; 李秀惠

doi:10.3969/j.issn.1001-5256.2018.04.040

药物性肝损伤发病机制研究进展

DOI: 10.3969/j.issn.1001-5256.2018.04.040

首都医科大学附属北京佑安医院中西医结合中心

基金项目:

重大新药创制国家科技重大专项(2015ZX09501004-001-002,2015ZX09501004-001-009)；北京市自然科学基金(7172103)；

详细信息

中图分类号: R575
计量
- 文章访问数: 2057
- HTML全文浏览量: 90
- PDF下载量: 487
- 被引次数: 0
出版历程
- 出版日期: 2018-04-20

Research advances in the pathogenesis of drug-induced liver injury

Department of Integrated Traditional Chinese and Western Medicine, Beijing YouAn Hospital, Capital Medical University

Research funding:

摘要

摘要: 近年来,由于临床药物的不合理应用、保健品及膳食补充剂成分不明确、药物安全知识普及不够等原因,药物性肝损伤(DILI)的病例逐年递增,并成为了肝衰竭及肝移植的重要原因。DILI的发病机制复杂,各医疗机构对DILI的关注度不断提高,其相关性的动物及细胞实验正在全球陆续开展,对其代谢途径、免疫机制、线粒体异常、基因学等方面的研究都取得了不同程度的进展,各种发病机制的深入研究和相互关系的探索,对揭示DILI的真正致病原因具有重大意义。综合了国内外与DILI发病相关的文献,阐述了其发病机制的研究概况,为临床治疗和基础研究提供参考。
- 药物性肝损伤 /
- 病理过程 /
- 综述
Abstract: In recent years, the number of drug-induced liver injury (DILI) cases is increasing year by year due to unreasonable drug use in clinical practice, unclear composition of healthcare products and dietary supplements, and a lack of drug safety knowledge, and DILI has become a major cause of liver failure and liver transplantation.DILI has complex pathogenesis, and medical institutions are paying more and more attention to DILI.Related animal and cell experiments are being conducted all over the world, and advances have been made in metabolic pathways, immune mechanism, mitochondrial abnormality, and genetics of DILI.In-depth research on various pathogeneses and their association helps to reveal the true pathogenesis of DILI.With reference to the articles on the pathogenesis of DILI in China and foreign countries, this article elaborates on the current research status of the pathogenesis of DILI and provides a reference for clinical treatment and basic research.
- drug-induced liver injury /
- pathologic processes /
- review

HTML全文

参考文献(56)

[1]BALE SS, VERNETTI L, SENUTOVITCH N, et al.In vitro platforms for evaluating liver toxicity[J].Exp Biol Med (Maywood) , 2014, 239 (9) :1180-1191.

[2]REN ZQ, WANG JH, LI H, et al.Multidisciplinary expert consensus on clinical features and prognosis of drug-induced liver injury[J].World Chin J Dig, 2016, 24 (8) :1257-1263. (in Chinese) 任张青, 王进海, 李浩, 等.药物性肝损伤临床特征及预后多学科专家共识[J].世界华人消化杂志, 2016, 24 (8) :1257-1263.

[3]LIU FF, DUAN XZ, ZANG H, et al.Analysis of the clinical characteristics of different types of drug-induced acute liver injury[J].Prog Mod Biomed, 2013, 13 (10) :1918-1921. (in Chinese) 柳芳芳, 段学章, 臧红, 等.不同类型急性药物性肝损伤的临床特点分析[J].现代生物医学进展, 2013, 13 (10) :1918-1921.

[4]YAO F, WANG YY.Statistic analysis of the 9355 patients with drug induced liver injury[J].Anhui Med Pharm J, 2011, 15 (10) :1312-1314. (in Chinese) 姚飞, 汪燕燕.综合分析药物性肝损伤9355例[J].安徽医药, 2011, 15 (10) :1312-1314.

[5]HU Q, LIU W, SHAO H.Research progress of pharmacotherapy drug-induced liver injury[J].Chin J Clin Pharmacol Ther, 2016, 21 (2) :231-236. (in Chinese) 胡琴, 刘维, 邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学, 2016, 21 (2) :231-236.

[6]SEBODE M, SCHULZ L, LOHSE AW."Autoimmune (-Like) "drug and herb induced liver injury:new insights into molecular pathogenesis[J].Int J Mol Sci, 2017, 18 (9) :1-22.

[7]HUANG CY, LIU YM, HUANG YL, et al.Drug-induced liver injury accompanied by autoimmune phenomena:an analysis of clinical characteristics[J].J Clin Hepatol, 2015, 31 (8) :1303-1306. (in Chinese) 黄春洋, 刘燕敏, 黄云丽, 等.药物性肝损伤患者伴自身免疫现象的临床特点分析[J].临床肝胆病杂志, 2015, 31 (8) :1303-1306.

[8]OSTAPOWICZ G, FONTANA RJ, SCHIODT FV, et al.Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J].Ann Intern Med, 2002, 137 (12) :947-954.

[9]KAPLOWITZ N.Case definition and phenotype standardization in drug-induced liver injury[J].Clin Pharmacol Ther, 2011, 89 (6) :806-815.

[10]KHOURY T, RMEILEH AA, YOSHA L, et al.Drug induced liver injury:review with a focus on genetic factors, tissue diagnosis, and treat-ment options[J].Clin Transl Hepatol, 2015, 3 (2) :99-108.

[11]LEE WM.Drug-induced acute liver failure[J].Clin Liver Dis, 2013, 17:575-586, viii.

[12]ANDRADE RJ, LUCENA MI, FERNANDEZ MC, et al.Drug-induced liver injury:an analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J].Gastroenterology, 2005, 129 (2) :512-521.

[13]LEWIS JH.Drug-induced liver disease[J].Med Clin North Am, 2000, 84 (5) :1275-1311.

[14]TENG GJ, SUN Y, CHANG BX, et al.The clinical features and prognosis analysis of 418 patients with drug-induced liver injury[J].Chin Hepatol, 2013, 18 (1) :11-14. (in Chinese) 滕光菊, 孙颖, 常彬霞, 等.418例药物性肝损害临床特征及预后分析[J].肝脏, 2013, 18 (1) :11-14.

[15]YAO YJ, LIU HL, ZHU B, et al.Analysis of clinical features and pathological change in 441 patients with drug-induced liver injuries[J].J Pract Hepatol, 2015, 18 (3) :286-289. (in Chinese) 姚云洁, 刘鸿凌, 朱冰, 等.441例药物性肝损伤患者临床和肝组织病理学特征分析[J].实用肝脏病杂志, 2015, 18 (3) :286-289.

[16]CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.

[17]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1768. (in Chinese) 中华医学会肝病学分会.药物性肝病学组药物性肝损伤诊治指南 (2015年版) [J].临床肝胆病杂志, 2015, 31 (11) :1752-1768.

[18]LUEDDE T, KAPLOWITZ N, SCHWABE RF.Cell death and cell death responses in liver disease:mechanisms and clinical relevance[J].Gastroenterology, 2014, 147 (4) :765-783.

[19]STEPHENS C, ANDRADE RJ, LUCENA MI.Mechanisms of drug-induced liver injury[J].Curr Opin Allergy Clin Immunol, 2014, 14:286-292.

[20]KAPLOWITZ N.Idiosyncratic drug hepatotoxicity[J].Nat Rev Drug Discov, 2005, 4 (6) :489-499.

[21]RUSSMANN S, JETTER A, KULLAK-UBLICK GA.Pharmacogenetics of drug-induced liver injury[J].Hepatology, 2010, 52 (2) :748-761.

[22]BROWNING BL, BROWNING SR.Haplotypic analysis of wellcome trust case control consortium data[J].Hum Genet, 2008, 123 (3) :273-280.

[23]GABRIEL SB, SCHAFFNER SF, NGUYEN H, et al.The structure of haplotype blocks in the human genome[J].Science, 2002, 296 (5576) :2225-2229.

[24]TANG NP, WANG Y, LI H, et al.Study on candidate biomarkers of drug liver toxicity based on genomics[C]//A collection of papers on science and technology of the fourth Chinese Youth Academy of Toxicology.2014:43. (in Chinese) 汤纳平, 王雁, 李华, 等.基于基因组学的药物肝毒性候选生物标志物的研究[C]//中国毒理学会第四届中青年学者科技论坛论文集.2014:43.

[25]KUBES P, MEHAL WZ.Sterile inflammation in the liver[J].Gastroenterology, 2012, 143 (5) :1158-1172.

[26]XU X, JI LS, LU LL, et al.Research advances in the pathogenesis of drug-induced liver injury[J].J Clin Hepatol, 2016, 32 (2) :382-385. (in Chinese) 许新, 纪莉莎, 芦琳琳, 等.药物性肝损伤发病机制的研究进展[J].临床肝胆病杂志, 2016, 32 (2) :382-385.

[27]FISHER K, VUPPALANCHI R, SAXENA R.Drug-induced liver injury[J].Arch Pathol Lab Med, 2015, 139:876-887.

[28]TAN XQ, YANG GQ, ZHANG L, et al.Research progress on CYP2E1 mediating toxicity by exogenous chemicals[J].China Occup Med, 2016, 43 (2) :234-236. (in Chinese) 谭孝琼, 杨光谦, 张林, 等.细胞色素P4502 E1介导外源性化合物毒性损伤研究进展[J].中国职业医学, 2016, 43 (2) :234-236.

[29]SHENG YJ, HE HY.Association between CYP2E1 and NAT2 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs:a meta-analysis[J].Infect Dis Info, 2017, 30 (4) :212-215. (in Chinese) 盛云建, 何鸿雁.CYP2E1和NAT2基因多态性与抗结核药物诱导的药物性肝损伤关系的荟萃分析[J].传染病信息, 2017, 30 (4) :212-215.

[30]WU X, LIU CL, XUE G, et al.Association between Chinese CYP2E1 polymorphisms and anti-tuberculosis drug-induced liver injury:a Meta analysis[J/CD].Chin J Clinicians:Electronic Edition, 2017, 11 (7) :1147-1152. (in Chinese) 武鑫, 刘春亮, 薛刚, 等.中国人细胞色素P450 2E1基因多态性与抗结核药物性肝损害关系的Meta分析[J/CD].中华临床医师杂志:电子版, 2017, 11 (7) :1147-1152.

[31]MARTINEZ-GIL N, FLORES-BELLVER W, AHENZAR-AROCA S, et al.CYP2E 1 in the human retinal pigmenl epithelium:expresion, activity and induction by ethanol[J].Invest Ophthalmol Vis Sci, 2015, 56 (11) :6855-6863.

[32]ROTH RA, GANEY PE.Intrinsic versus idiosyncratic drug-induced hepatotoxicity——two villains or one?[J].J Pharmacol Exp Ther, 2010, 332 (3) :692-697.

[33]ZHANG J, JIN Z, HU XX, et al.Efficient two-photon fluorescent probe for glutathione S-transferase detection and imaging in druginduced liver injury sample[J].Anal Chem, 2017, 89 (15) :8097-8103.

[34]JIANG J, ZHANG X, HUO R, et al.Association study of UGT1A9promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population[J].Pharmacogenomics J, 2015, 15 (4) :326-331.

[35]YLVA T, FIGLER RA, SVETLANA M, et al.Transcriptional profiling suggests that nevirapine and ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes[J].Chem Biol Interact, 2016, 255:31-44.

[36]STICKEL F.Letter to the editor“Genetic polymorphisms in the UDP-glucuronosyltransferase UGT1A7 gene in patients with acute liver failure after kava-kava consumption”[J].Arch Toxicol, 2015, 89 (11) :2175-2176.

[37]ZOLNER G, TRAUNER M.Molecular mechanism of cholestasis[J].Wien Med Wochenschr, 2006, 156 (13-14) :380-385.

[38]FONTANA RJ.Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J].Gastroenterology, 2014, 146 (4) :914-928.

[39]KARCZMAREK-BOROWSKA B, SANEK-ZA N'A.Hepatotoxicity of molecular targeted therapy[J].Contemp Oncol (Pozn) , 2015, 19:87-92.

[40]KLEINER DE, CHALASANI NP, LEE WM, et al.Hepatic histological findings in suspected drug-induced liver injury:systematic evaluation and clinical associations[J].Hepatology, 2014, 59 (2) :661-670.

[41]PETROS Z, KISHIKAWA J, MAKONNEN E, et al.HLA-B*57Allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in ethiopians[J].Front Pharmacol, 2017, 8:90.

[42]ZHANG ST, WAN GJ, LI L.Research advances in the mechanism of drug-induced liver injury[J].Pharm Care Res, 2017, 17 (1) :39-42. (in Chinese) 张守堂, 万国靖, 李璐.药物性肝损伤机制的研究进展[J].药学服务与研究, 2017, 17 (1) :39-42.

[43]BOELSTERLI UA, LEE KK.Mechanisms of isoniazid-induced idiosyncratic liver injury:emerging role of mitochondrial stress[J].J Gastroenterol Hepatol, 2014, 29 (4) :678-687.

[44]BHADAURIA S, MISHRA R, KANCHAN R, et al.Isoniazid-induced apopto-sis in Hep G2 cells:generation of oxidative stress and Bcl-2 down-regulation[J].Toxicol Mech Methods, 2010, 20:242-251.

[45]RAMACHANDRAN A, LEBOFSKY M, WEINMAN SA, et al.The impact of partial manganese superoxide dismutase (SOD2) -deficiency on mitochondrial oxidant stress, DNA fragmentation and liver injury during acetaminophen hepatotoxicity[J].Toxicol Appl Pharmacol, 2011, 251 (3) :226-233.

[46]LEE SJ, LEE YJ, PARK KK.The pathogenesis of drug-induced liver injury[J].Expert Rev Gastroenterol Hepatol, 2016, 10 (10) :1-11.

[47]LUCENA MI, GARCIA-MARIFN E, ANDRADE RJ, et al.Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induce liver injury[J].Hepatology, 2010, 52 (1) :303-312.

[48]ANTONIADES CG, KHAMRI W, ABELES RD, et al.Secretory leukocyte protease inhibitor:a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure[J].Hepatology, 2014, 59 (4) :1564-1576.

[49]TAO MB, ZHANG L, LIU F, et al.Contains anthraquinones constituents of traditional Chinese medicine security research progress[C].Chinese Medicine and Natural Drug Toxicology Specialized Committee of Chinese Society of Toxicology First (2016) Academic Conference, 2016:108-115. (in Chinese) 陶明宝, 张乐, 刘飞, 等.含蒽醌类成分中药的安全性研究进展[C].中国毒理学会中药与天然药物毒理专业委员会第一次 (2016年) 学术交流大会, 2016:108-115.

[50]MA K, LIU YL.Research Progress on drug induced liver injury caused by traditional Chinese medicine[J].Guangming J Chin Med, 2015, 30 (4) :907-911. (in Chinese) 马昆, 刘燕玲.中药引起的药物性肝损伤研究进展[J].光明中医, 2015, 30 (4) :907-911.

[51]Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine.Guidelines for the clinical management of herb-induced liver injury[J].J Clin Hepatol, 2016, 32 (5) :835-843. (in Chinese) 中华中医药学会肝胆病分会, 中华中医药学会中成药分会.中草药相关肝损伤临床诊疗指南[J].临床肝胆病杂志, 2016, 32 (5) :835-843.

[52]PARK EJ, ZHAO YZ, KIM YC, et al.Bakuchiol-induced caspase-3-dependent apoptosis occurs through c-Jun NH2-terminal kinase-mediated mitochondrial translocation of Bax in rat liver myofibroblasts[J].Eur J Pharmacol, 2007, 559 (2-3) :115-123.

[53]LI B, LI L, ZHAO JN, et al.Effect of Wu Zhuyu ethanol extract on acute toxicity and hepatotoxicity in rats[J].Pharmocol Clin Chin Mater Med, 2013, 29 (2) :120-124. (in Chinese) 李波, 李莉, 赵军宁, 等.吴茱萸乙醇提取物对大鼠急性毒性及肝毒性的影响[J].中药药理与临床, 2013, 29 (2) :120-124.

[54]MEI X, YU LQ, CHEN XY, et al.Advances in studies on the chemical components and pharmacological activities of Radix Polygoni multiflori[J].Drug Eval Res, 2016, 39 (1) :122-131. (in Chinese) 梅雪, 余刘勤, 陈小云, 等.何首乌化学成分和药理作用的研究进展[J].药物评价研究, 2016, 39 (1) :122-131.

[55]WANG Y, LI J, WU Z, et al.Insights into the molecular mechanisms of Polygonum multiflorum Thunb-induced liver injury:a computational systems toxicology approach[J].Acta Pharmacol Sin, 2017, 38 (5) :719-732.

[56]SU YW, CHEN X, JIANG ZZ, et al.A panel of serum microRNAs as specific biomarkers for diagnosis of compound-and herb-induced liver injury in rats[J].PLo S One, 2012, 7 (5) :e37395.

施引文献

资源附件(0)

访问统计